APSR2026-1082

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP11-030
P72
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1242420-46904-LOGOS_APSR26 Poster_FEV_Final_436465.pdf
Format: PDF Only
09. Asthma
15

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Ruchong Chen * Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University State Key Laboratory of Respiratory Disease, National Clinical Research Center for Respiratory Disease, National Center for Respiratory Medicine, Joint International Research Laboratory of Respiratory Health, Department of Allergy and Clinical Immunology Guangzhou China
Mehul Patel - AstraZeneca Respiratory, BioPharmaceuticals R&D Cambridge United Kingdom
Teodora Trasieva - AstraZeneca Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D Gothenburg Sweden
Charlotta Movitz - AstraZeneca Respiratory and Immunology, Biometrics, BioPharmaceuticals R&D Gothenburg Sweden
Jonathan Marshall - AstraZeneca BioPharmaceuticals Medical Cambridge United Kingdom
Bi Chen - The Affiliated Hospital of Xuzhou Medical University Department of Pulmonary and Critical Care Medicine Xuzhou China
Jinghao Zhang - Xuzhou Central Hospital Department of Pulmonary and Critical Care Medicine Xuzhou China
Zuke Xiao - iangxi Provincial People’s Hospital Department of Pulmonary and Critical Care Medicine Nanchang China
Daoxin Wang - The Second Affiliated Hospital of Chongqing Medical University Department of Pulmonary and Critical Care Medicine Chongqing China
Yi Jiang - First Hospital of Shanxi Medical University Department of Pulmonary and Critical Care Medicine Taiyuan China
Xingxiang Xu - Northern Jiangsu People’s Hospital Department of Respiratory and Critical Care Medicine Yangzhou China
Yu Xia - The First Affiliated Hospital of Xinjiang Medical University Department of Pulmonary and Critical Care Medicine Urumqi China
Zongxing Ou - Haikou People’s Hospital Department of Pulmonary and Critical Care Medicine Haikou China
Wei Wang - The First Affiliated Hospital of China Medical University Department of Pulmonary and Critical Care Medicine Shenyang China
Zili Meng - Huai'an First People's Hospital Department of Pulmonary and Critical Care Medicine Huai'an China
Presenting Author Details
Ruchong
Chen
chen_rch@163.com
+8613710723826
41-50
China
Original Research
Budesonide-glycopyrronium-formoterol fumarate dihydrate effects on lung function in uncontrolled asthma: findings from the China subgroup of the phase 3 LOGOS study
Maximum 25 words
Abstract Content
LOGOS (NCT04609904) was a multicentre, randomised, double-blind, double-dummy, parallel-group, phase 3 trial, evaluating budesonide-glycopyrronium-formoterol fumarate dihydrate (BGF) in uncontrolled asthma. We described baseline characteristics and lung function outcomes in China subgroup.
Patients (12–80 years) with uncontrolled asthma despite daily medium-/high-dose inhaled corticosteroid (ICS)–long-acting β2-agonist (LABA) were enrolled. After a 4-week run-in, they were randomised to BGF 320/28.8/10 μg (BGF 28.8), BGF 320/14.4/10 μg (BGF 14.4), budesonide-formoterol fumarate dihydrate (BFF) 320/10 μg via co-suspension technology (BFFA) or BFF 320/9 μg in current suspension formulation (BFFS), twice daily for 24–52 weeks. Lung function endpoints included changes from baseline in morning pre-dose trough FEV1 and in FEV1 area under curve 0–3 h (AUC0–3).
794 patients were analysed in China subgroup (BGF 28.8: n=210; BGF 14.4: n=156; BFFA: n=214; BFFS: n=214). Median (range) age was 55.0 (13–78) years; 44.8% were male. 85.6% of patients had never smoked. At baseline, mean (SD) ACQ-7 score was 2.27 (0.40). 71.8% of patients had no severe exacerbations in the prior year, higher than in global population (50.6%). Mean pre-bronchodilator FEV1 was 1,589 (530) mL and mean pre-bronchodilator FEV1%predicted was 57.8 (13.4) %. Mean percentage reversibility was 19.9 (14.9) %, with 42.3% having reversibility ≥20%. Mean blood eosinophil count was 211.5 (165.0) cells/mm3. 87.2% and 12.8% of patients were receiving medium- and high-dose ICS. Over 24 weeks, BGF 28.8 improved morning pre-dose trough FEV1 and FEV1 AUC0–3 versus BFFS by 131 (95% CI: 84–179) mL and 137 (93–181) mL, respectively (Table 1).
Among Chinese patients with uncontrolled asthma in LOGOS, baseline exacerbation burden appeared lower than in global population, whereas lung function benefits with BGF were directionally consistent and numerically greater. In Chinese patients, BGF triple therapy improved lung function versus BFF dual therapy regardless of recent exacerbation history.
 
 
 
 
 
No
Yes
https://storage.unitedwebnetwork.com/files/1285/1242420-37089-FEVtable_400637.png
JPG or JPEG or PNG format ONLY
budesonide/glycopyrronium/formoterol, lung function, Chinese population
maximum 3 keywords and no abbreviations, separated by commas
The authors would like to thank all researchers and patients involved in the study across all research centers. The authors acknowledge the late Professor Huahao Shen for his important contributions to the study design and conduct. The authors acknowledge Bingyu Bai, from Costello Medical, Singapore, for medical writing and editorial assistance, funded by AstraZeneca, which were in accordance with the Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research.
334